Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Cancer Genetics, Inc. Receives Regulatory Approvals for MatBA®-DLBCL

Published: Wednesday, February 27, 2013
Last Updated: Wednesday, February 27, 2013
Bookmark and Share
MatBA®-DLBCL is a proprietary microarray test for the diagnosis, prognosis, and patient risk stratification of non-Hodgkin Lymphoma.

Cancer Genetics, Inc. (CGI) announced it has received CLIA and New York State approvals for clinical use of its proprietary mature B-cell neoplasm array or MatBA® (patent 13/475,034) for diffuse large B-cell lymphoma. MatBA®-DLBCL will assist clinicians in the diagnosis and prognosis of DLBCL.

DLBCL is the most common form of non-Hodgkin lymphoma (NHL), a diverse group of hematological malignancies. An estimated 190,000 people in the United State suffer from DLBCL, and up to 24,500 new U.S. cases diagnosed each year, which accounts for up to 40% of all NHL cases. Newly-diagnosed patients have a median age of 64 years, and disease progression and outcomes vary widely, due in part to the genomic characteristics of each individual patient’s cancer. This creates a strong clinical need for accurate and molecularly-informed prognostic testing both at the time of initial diagnosis and throughout ongoing disease monitoring efforts to ensure selection of the best treatment plan for an individual patient. However, current prognostic modalities rely primarily on clinical features.

CGI’s MatBA®-DLBCL microarray provides clinicians with information on genomic alterations in DLBCL, including regions of gain and loss that are associated with disease outcome.

A research collaboration between the Memorial Sloan-Kettering Cancer Center and CGI using 87 patient samples, as well as the analysis of two open datasets including 171 samples (GSE11318, Lenz et al.) and 51 high risk samples (E-MEXP-3463, Taskinen) and other published datasets showed that:

•    MatBA®-DLBCL has both diagnostic and prognostic value
•    MatBA®-DLBCL can assist in patient stratification for risk-adapted therapy when performed at diagnosis
•    MatBA®-DLBCL assesses the presence of single biomarkers as well as genome complexity as measures of overall survival following front-line immunochemotherapy

CGI believes that it is the only laboratory to have a CLIA and New York State approved microarray for the genomic assessment of DLBCL. The MatBA®-DLBCL Array CGH assay joins the DLBCL CompleteSM program offered by CGI, which includes a suite of esoteric tests used in the diagnosis, prognosis and clinical management of DLBCL patients. This newly-approved DLBCL test extends CGI’s ongoing commitment to developing new diagnostic and disease management tools for some of the most costly and critical unmet needs in oncology today. MatBA®-DLBCL joins MatBA®-CLL (chronic lymphocytic leukemia) and MatBA®-SLL (small lymphocytic leukemia) in CGI’s suite of CLIA- and New York State-approved proprietary microarrays for the clinical management of underserved hematological malignancies.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Cancer Cells Kill Off Healthy Neighbours
Cancer cells create space to grow by killing off surrounding healthy cells, according to UK researchers working with fruit flies.
Cancer Drug Target Visualized at Atomic Resolution
New study using cryo-electron microscopy shows how potential drugs could inhibit cancer.
Genetic Mechanism Behind Cancer-Causing Mutations
Researchers at Indiana University has identified a genetic mechanism that is likely to drive mutations that can lead to cancer.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
"Gene Fusion" Drives Childhood Brain Cancers
Study co-led by Penn scientists highlights potential targets for future cancer therapies.
Enzyme Links Age-Related Inflammation, Cancer
Researchers have shown that an enzyme key to regulating gene expression -- and also an oncogene when mutated -- is critical for the expression of numerous inflammatory compounds that have been implicated in age-related increases in cancer and tissue degeneration.
Viral Gene Editing System Corrects Genetic Liver Disease
Penn study has implications for developing safe therapies for an array of rare diseases via new gene cut-and-paste methods.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Curing Disease by Repairing Faulty Genes
New delivery method boosts efficiency of CRISPR genome-editing system.
'Junk' DNA Plays Role in Preventing Breast Cancer
Supposed "junk" DNA, found in between genes, plays a role in suppressing cancer, according to new research by Universities of Bath and Cambridge.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!